goBalto has raised $12 million for its software-as-a-service clinical research platform, according to an SEC filing, bringing the company’s total funding to at least $30 million to date. Existing goBalto investors include Aberdare, EDBI, Qualcomm Health, and West Health.

GoBalto’s main product, Activate (formerly Tracker 2.0), provides a clinical research platform for “study startup”, which is the process that includes collecting, reviewing, and approving hundreds or thousands of clinical documents needed in a clinical trial. In addition, the solution also helps researchers track milestones during a trial, provide document workflow management, and create a to-do list of required activities.

The company raised its last round of funding in March 2014. At that time, CEO Sujay Jadhav said goBalto had two different types of customers – the contract research organizations (CROs) such as Inc Research and Icon, and the pharma organizations like Novartis and Shire. These customers, Jadhav said, had run multiple studies through goBalto’s platform, and planned to scale the offering across a majority of their studies.

[Via: mobihealthnews]